Cyteir Therapeutics (Cyteir Therapeutics) Net Cash per Share : $3.42 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Cyteir Therapeutics's Net Cash per Share for the quarter that ended in Sep. 2023 was $3.42.

The historical rank and industry rank for Cyteir Therapeutics's Net Cash per Share or its related term are showing as below:

CYTT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.42 Med: 0.77 Max: 3.84
Current: 0.88

During the past 4 years, the highest Price-to-Net-Cash Ratio of Cyteir Therapeutics was 3.84. The lowest was 0.42. And the median was 0.77.

CYTT's Price-to-Net-Cash is ranked better than
88.7% of 867 companies
in the Biotechnology industry
Industry Median: 3.92 vs CYTT: 0.88

Cyteir Therapeutics Net Cash per Share Historical Data

The historical data trend for Cyteir Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Net Cash per Share Chart

Cyteir Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Net Cash per Share

-1.58

-1.47

5.16

3.95

Cyteir Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Cash per Share	Get a 7-Day Free Trial											4.14	3.95	3.74	3.53	3.42

Competitive Comparison of Cyteir Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Cyteir Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyteir Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Price-to-Net-Cash falls into.

Cyteir Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Cyteir Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

	Net Cash per Share (A: Dec. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(147.12	-	6.946	-	0)	/	35.5163
=	3.95

Cyteir Therapeutics's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

	Net Cash per Share (Q: Sep. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(129.242	-	5.978	-	0)	/	36.0837
=	3.42

Cyteir Therapeutics (OTCPK:CYTT) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Cyteir Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421

Website

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness	officer: General Counsel	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey	director	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong	director	69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven	10 percent owner	BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421